🚨 Drug Pricing System

Today Korean Social News for Beginners | 2026.03.27

0️⃣ First Major Drug Pricing Reform in 14 Years — Cutting Costs While Improving Access to New Medicines

📌 Lower Generic Prices, Faster Rare Disease Listings… A Full Overhaul of Korea's Drug Pricing System

💬 The government has announced a major overhaul of the national health insurance drug pricing system — the first in 14 years. The price of generic drugs will be reduced from 53.55% to 45% of the original drug price, saving up to ₩2.4 trillion per year. At the same time, the period for listing rare disease treatments under insurance will be cut from 240 days to 100 days, so patients can access new drugs much faster. Innovative pharmaceutical companies will receive a 60% price bonus guaranteed for up to four years. A stronger system to ensure stable supplies of essential medicines will also be introduced. The reform aims to balance financial sustainability of the health insurance fund with support for pharmaceutical innovation.

💡 Summary

• The drug pricing system is how the government decides and manages the prices of medicines covered by national health insurance.
• The reform lowers generic drug prices to save money, while giving stronger incentives to companies developing new innovative drugs.
• The listing period for rare disease treatments will be greatly shortened, so patients can receive prescriptions for new drugs much sooner.

1️⃣ Definition

The drug pricing system is a system where the government decides and manages the prices of medicines that doctors can prescribe to patients under national health insurance. In simple terms, when you pick up a prescription at a pharmacy, you don't pay the full price — national health insurance pays most of it. The government controls how much that price is.

When you get medicine at a pharmacy and only pay a small portion of the cost, that's because of the health insurance benefit system. The government decides which drugs are covered and at what price. The key challenge is balancing three goals at once: keeping the health insurance fund financially sustainable, making sure patients can afford the medicines they need, and encouraging pharmaceutical companies to develop new drugs.

💡 Why does this matter?

• If drug prices are too high, the health insurance fund runs out faster, and everyone's premiums go up.
• If prices are too low, pharmaceutical companies have less reason to invest in developing new drugs, which is bad for public health in the long run.
• Patients with rare diseases may not be able to access expensive treatments in time — faster listing can be a matter of life and death.
• This is the biggest reform in 14 years and will have a major impact on both patients and the pharmaceutical industry.

2️⃣ Current Situation and Key Issues

📕 Main Points of the Reform

• Generic drug prices will be cut to save health insurance funds. Key details include:

  • The price of generic drugs will drop from 53.55% to 45% of the original drug's price.
  • This is expected to save up to ₩2.4 trillion per year in health insurance drug costs.
  • This is a key step to keeping the health insurance system financially sustainable.
  • The pharmaceutical industry is worried about lower profits, so negotiations with the industry will be needed.

• Innovative medicines will receive stronger incentives. Key details include:

  • Companies certified as "innovative pharmaceutical companies" will receive a 60% price bonus guaranteed for up to four years.
  • Companies certified at the "semi-innovative" level will receive a 50% price bonus.
  • The time to list rare disease treatments under health insurance will be cut dramatically — from 240 days to 100 days.
  • The risk-sharing agreement system will be expanded to make it easier for expensive new drugs to be covered.

📕 Challenges and Issues

• Cutting generic drug prices has two sides — saving money vs. burdening the industry. Key issues include:

  • Lower generic prices help the health insurance fund, but could cause financial difficulties for small and mid-sized pharmaceutical companies.
  • If prices fall too low, companies may cut corners on drug quality management.
  • Essential medicines may stop being produced if they are no longer profitable, causing supply shortages — a problem that has happened before.
  • If the pharmaceutical industry shrinks, South Korea's ability to develop new drugs over the long term may weaken.

• Faster listing for rare disease drugs brings both hope and challenges. Key points include:

  • Shorter listing periods mean patients with rare diseases can receive new drug prescriptions much sooner.
  • However, a shorter review period may mean that the cost-effectiveness of drugs is not fully verified.
  • Covering more expensive rare disease treatments under insurance could put additional pressure on the health insurance fund.
  • The key is using risk-sharing agreements to strike the right balance between financial burden and patient access.

• The system for ensuring stable supplies of essential medicines will also be strengthened. Key directions include:

  • Since COVID-19, unstable medicine supply chains have been a recurring problem, making a response system urgent.
  • Companies that produce essential medicines will receive price bonuses to encourage stable production.
  • Medicine stockpiling systems and supply monitoring will be improved.
  • Whether this system will actually work in a real medical crisis still needs to be verified going forward.

💡 Key Issues in This Reform

1. Saving money vs. industry burden: Cutting generic prices helps the insurance fund but hurts pharmaceutical company profits
2. Faster listing vs. less review: Shorter listing periods improve patient access but may not allow enough time for proper evaluation
3. Whether innovation incentives will work: Unclear if guaranteed price bonuses will actually lead to more investment in new drug development
4. Supply instability: Lower prices could reduce production of essential medicines
5. Growing financial pressure: Covering more expensive new drugs could increase strain on health insurance finances

3️⃣ Reform Directions

✅ Making Drug Pricing More Rational

• The pace and scale of generic drug price cuts should be gradual. Key directions include:
  • Instead of sharp sudden cuts, a step-by-step schedule that gives the industry time to adjust is needed.
  • A minimum price level that maintains drug quality and supply stability must be guaranteed.
  • Some of the money saved from price cuts should be reinvested to cover more innovative new drugs.
  • Drug pricing standards should be reviewed regularly to respond flexibly to market changes.

✅ Improving Patient Access

• Access to new drugs for rare disease and serious illness patients must continue to improve. Key tasks include:
  • Fast-track listing should be maintained, but safety and effectiveness review standards must not be lowered.
  • The risk-sharing agreement system should be expanded, with clear standards for measuring outcomes and refunds.
  • Patient groups and medical professionals should have a meaningful voice in coverage decisions.
  • Support systems for expensive uncovered drugs should be strengthened to reduce gaps in protection.

4️⃣ Key Terms Explained

🔎 Generic Drug

• A generic drug is a copy of a brand-name drug made after the patent expires.
  • A generic drug is made using the same active ingredient as the original brand-name drug, but produced after the patent protection period ends. It can be sold once it passes a bioequivalence test — a test proving it works the same way as the original.
  • Generic drugs are much cheaper than original brand-name drugs because the manufacturer doesn't have to spend hundreds of billions of won on research and development. Thanks to generics, drugs that have gone off-patent can be supplied at a much lower cost with the same effect. About 80% of all prescription drugs worldwide are generics, and they play a key role in keeping health insurance costs manageable.
  • This reform lowers the pricing rate for generics so that health insurance premiums are spent more efficiently. However, if prices fall too low, pharmaceutical companies may stop producing certain generics, so finding the right balance is important.

🔎 Drug Price Bonus System

• The drug price bonus system gives higher prices to medicines that meet certain conditions.
  • The drug price bonus system is designed to encourage pharmaceutical companies to invest in areas that are socially important but not very profitable — like developing new drugs or producing treatments for rare diseases — by allowing them to charge a higher price than the standard rate.
  • Companies certified as "innovative pharmaceutical companies" can receive up to a 60% price bonus, and "semi-innovative" companies can receive 50%. A key feature of this reform is guaranteeing these bonuses for up to four years, giving companies more predictability when making investment decisions.
  • For pharmaceutical companies, knowing how long they will receive price benefits from a new drug makes it much easier to decide whether to invest. It's similar to how a property developer needs a guaranteed lease period before deciding to build.

🔎 Risk-Sharing Agreement

• A risk-sharing agreement is a system where the government and a pharmaceutical company share the cost based on how well a new drug actually works.
  • A risk-sharing agreement (RSA) allows a new expensive drug to be listed under health insurance coverage on the condition that the pharmaceutical company refunds part of the cost or offers a discount if the drug does not perform well enough.
  • For example, an agreement might say: "If at least 50% of patients respond well to this cancer drug, full coverage applies — if fewer do, the company refunds part of the cost." Patients get treated quickly, and the government gets money back if the drug doesn't perform as promised.
  • RSAs are mainly used for cancer drugs and rare disease treatments — medicines that are very expensive but don't yet have enough clinical data. They are seen as a reasonable compromise that reduces financial risk while improving patient access.

🔎 Coverage Revaluation

• Coverage revaluation is a process of reviewing whether drugs already covered by health insurance are still worth the cost.
  • Even after a drug is included in the health insurance coverage list, more effective alternatives may appear over time, or the drug's cost-effectiveness may decline. Coverage revaluation is a system that periodically reviews these drugs to decide whether to continue coverage or adjust the price.
  • It acts as a safeguard to make sure limited health insurance funds are focused on the most effective treatments. If a drug is found to have low clinical benefit or poor cost-effectiveness during revaluation, it may be removed from coverage or have its price reduced — this keeps pharmaceutical companies motivated to continue researching their drugs.
  • As medical technology advances rapidly, some drugs that were listed decades ago are no longer the best option by current standards, so there is ongoing discussion about shortening the revaluation cycle and strengthening the criteria.

5️⃣ Frequently Asked Questions (FAQ)

Q: Will my out-of-pocket drug costs change because of this reform?

A: If you are prescribed generic drugs, your out-of-pocket cost may decrease slightly.

• When health insurance pays a lower price for a drug, the overall drug price baseline falls — which can lower what patients pay out of pocket as well. If you are a chronic illness patient who is often prescribed generic drugs, you may notice the benefit over time.
• On the other hand, for expensive new drugs for rare diseases or serious illnesses that are newly added to coverage, the change is even more significant. Before coverage, patients had to pay the full price. After coverage, they only pay a portion — a major benefit. The shortened listing period for rare disease treatments means patients can start receiving this benefit much sooner.

Q: If pharmaceutical companies earn less, won't new drug development decrease?

A: There may be some short-term pressure, but the incentives for innovative companies are designed to offset this.

• Generic drug price cuts may hurt the profitability of small and mid-sized pharmaceutical companies that focus mainly on producing copycat drugs. However, this reform also strengthens guaranteed price bonuses for innovative pharmaceutical companies. The system is designed so that companies that invest in research and development receive higher prices for longer — encouraging them to focus on new drug development rather than just making generics.
• In the long term, this could help shift the structure of South Korea's pharmaceutical industry from a generic-dominated model toward an innovation-focused one. However, if supplementary measures are not put in place to ease the burden on smaller companies, rapid industry restructuring could create gaps in the supply of essential medicines — so getting the policy mix right is crucial.

Q: What does the shorter listing period for rare disease treatments mean for me?

A: If you have a rare disease, you will be able to receive prescriptions for new drugs under health insurance much sooner.

• Until now, it took an average of 240 days — about eight months — for a rare disease treatment approved overseas to receive health insurance coverage in South Korea. With this reform cutting that to 100 days, patients will be able to get covered prescriptions for expensive treatments much faster.
• Rare diseases often leave very narrow treatment windows, where timing is critical. Delays in listing can mean lost treatment opportunities. Shortening the listing period is the most direct and impactful change patients and their families will feel. That said, it's also important to check that faster listing decisions are not skipping necessary reviews of safety and effectiveness — the quality of the review process matters too.

View Index

• Go to Guide